194 related articles for article (PubMed ID: 36883413)
21. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
[TBL] [Abstract][Full Text] [Related]
22. Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first-in-class proof-of-concept phase 2 study.
Lee JM; Nair J; Zimmer A; Lipkowitz S; Annunziata CM; Merino MJ; Swisher EM; Harrell MI; Trepel JB; Lee MJ; Bagheri MH; Botesteanu DA; Steinberg SM; Minasian L; Ekwede I; Kohn EC
Lancet Oncol; 2018 Feb; 19(2):207-215. PubMed ID: 29361470
[TBL] [Abstract][Full Text] [Related]
23. ZNF671 DNA methylation as a molecular predictor for the early recurrence of serous ovarian cancer.
Mase S; Shinjo K; Totani H; Katsushima K; Arakawa A; Takahashi S; Lai HC; Lin RI; Chan MWY; Sugiura-Ogasawara M; Kondo Y
Cancer Sci; 2019 Mar; 110(3):1105-1116. PubMed ID: 30633424
[TBL] [Abstract][Full Text] [Related]
24. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
[TBL] [Abstract][Full Text] [Related]
25. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer.
Choi J; Topouza DG; Tarnouskaya A; Nesdoly S; Koti M; Duan QL
BMC Cancer; 2020 May; 20(1):413. PubMed ID: 32404140
[TBL] [Abstract][Full Text] [Related]
26. Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial-mesenchymal transition interlinked with reprogrammed metabolism.
Leung D; Price ZK; Lokman NA; Wang W; Goonetilleke L; Kadife E; Oehler MK; Ricciardelli C; Kannourakis G; Ahmed N
J Transl Med; 2022 Dec; 20(1):556. PubMed ID: 36463238
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
[TBL] [Abstract][Full Text] [Related]
28. Chromosome instability is prevalent and dynamic in high-grade serous ovarian cancer patient samples.
Morden CR; Farrell AC; Sliwowski M; Lichtensztejn Z; Altman AD; Nachtigal MW; McManus KJ
Gynecol Oncol; 2021 Jun; 161(3):769-778. PubMed ID: 33714608
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.
Bonito NA; Borley J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Brown R
Clin Cancer Res; 2016 Jun; 22(12):3097-3104. PubMed ID: 26763252
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
31. Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study.
Dugo M; Devecchi A; De Cecco L; Cecchin E; Mezzanzanica D; Sensi M; Bagnoli M
Genes (Basel); 2019 Sep; 10(9):. PubMed ID: 31491988
[TBL] [Abstract][Full Text] [Related]
32. The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma.
Smith P; Bradley T; Gavarró LM; Goranova T; Ennis DP; Mirza HB; De Silva D; Piskorz AM; Sauer CM; Al-Khalidi S; Funingana IG; Reinius MAV; Giannone G; Lewsley LA; Stobo J; McQueen J; Bryson G; Eldridge M; ; Macintyre G; Markowetz F; Brenton JD; McNeish IA
Nat Commun; 2023 Jul; 14(1):4387. PubMed ID: 37474499
[TBL] [Abstract][Full Text] [Related]
33. Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.
Fang L; Wang H; Li P
Invest New Drugs; 2018 Apr; 36(2):187-194. PubMed ID: 29082457
[TBL] [Abstract][Full Text] [Related]
34. PTPN13 Participates in the Regulation of Epithelial-Mesenchymal Transition and Platinum Sensitivity in High-Grade Serous Ovarian Carcinoma Cells.
Aptecar L; Puech C; Lopez-Crapez E; Peter M; Coopman P; D'Hondt V; Freiss G
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895093
[TBL] [Abstract][Full Text] [Related]
35. Molecular characterization of 7 new established cell lines from high grade serous ovarian cancer.
Kreuzinger C; Gamperl M; Wolf A; Heinze G; Geroldinger A; Lambrechts D; Boeckx B; Smeets D; Horvat R; Aust S; Hamilton G; Zeillinger R; Cacsire Castillo-Tong D
Cancer Lett; 2015 Jul; 362(2):218-28. PubMed ID: 25862976
[TBL] [Abstract][Full Text] [Related]
36. Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant.
Gershenson DM; Sun CC; Bodurka D; Coleman RL; Lu KH; Sood AK; Deavers M; Malpica AL; Kavanagh JJ
Gynecol Oncol; 2009 Jul; 114(1):48-52. PubMed ID: 19361839
[TBL] [Abstract][Full Text] [Related]
37. Differential DNA methylation in high-grade serous ovarian cancer (HGSOC) is associated with tumor behavior.
Reyes HD; Devor EJ; Warrier A; Newtson AM; Mattson J; Wagner V; Duncan GN; Leslie KK; Gonzalez-Bosquet J
Sci Rep; 2019 Nov; 9(1):17996. PubMed ID: 31784612
[TBL] [Abstract][Full Text] [Related]
38. Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Konstantinopoulos PA; Cheng SC; Wahner Hendrickson AE; Penson RT; Schumer ST; Doyle LA; Lee EK; Kohn EC; Duska LR; Crispens MA; Olawaiye AB; Winer IS; Barroilhet LM; Fu S; McHale MT; Schilder RJ; Färkkilä A; Chowdhury D; Curtis J; Quinn RS; Bowes B; D'Andrea AD; Shapiro GI; Matulonis UA
Lancet Oncol; 2020 Jul; 21(7):957-968. PubMed ID: 32553118
[TBL] [Abstract][Full Text] [Related]
39. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
[TBL] [Abstract][Full Text] [Related]
40. Primary and acquired platinum-resistance among women with high grade serous ovarian cancer.
Slaughter K; Holman LL; Thomas EL; Gunderson CC; Lauer JK; Ding K; McMeekin DS; Moore KM
Gynecol Oncol; 2016 Aug; 142(2):225-30. PubMed ID: 27208536
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]